Advanced glycation endproducts (AGEs): Pharmacological inhibition in diabetes

Area of Science:

• Biochemistry
• Pharmacology
• Diabetology

Background:

• Advanced glycation endproducts (AGEs) contribute to diabetic complications.
• Multiple mechanisms underlie AGE formation and AGE-mediated damage, including oxidative and carbonyl stress.

Purpose of the Study:

• To review the mechanisms of action for various AGE inhibitors.
• To summarize preclinical and clinical findings on AGE inhibitors in diabetes management.

Main Methods:

• Review of in vitro and in vivo studies on AGE inhibitors.
• Analysis of clinical trial data for AGE inhibitors and breakers.
• Categorization of inhibitors based on their therapeutic targets (e.g., AGE breakers, RAGE blockers).

Main Results:

• AGE inhibitors act through diverse mechanisms, such as trapping reactive carbonyls, antioxidant activity, cross-link breaking, and RAGE pathway modulation.
• Preclinical studies in diabetic animals show encouraging results for many AGE inhibitors.
• Clinical trials have been largely disappointing, often due to side effects.

Conclusions:

• While AGE inhibitors demonstrate potential in preclinical models, their clinical efficacy in diabetes remains uncertain.
• Further research is required to establish the long-term therapeutic value of novel AGE inhibitors and breakers.
• The development of effective AGE inhibitors faces challenges related to efficacy and side effect profiles.